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Background: Gender differences in heart transplant (HT) outcomes are well known. However, differences among those bridged with LVAD (BTT) 
have not been well studied. We sought to examine the mortality differences in this population.
methods: 3020 BTT HT patients (exclusions:< 18y, multiorgan, follow up loss) were identified from UNOS (2005-11) & stratified by sex. Survival 
was censored at 5y. Multivariate Cox proportional hazard regression analysis was adjusted for age, DM, ischemic time, ethnicity, dialysis, life support, 
wait time & HLA mismatch.
results: Of 3020, 18% were women. Ischemic (22% & 45%, male (M) & female (F) respectively) & dilated cardiomyopathy (69% (M) & 49% (F)) 
were the most prevalent diagnoses. Women were significantly younger than men & were associated with lower BMI, less prior cardiac surgery, better 
renal function, & lower filling pressures (Table). There was a trend towards increased LVAD usage in women (p=0.054). Survival (1, 3, 5y) was: F (86, 
78, 70%) & M (88, 81, 74%). Unadjusted HR for all-cause mortality was 0.85 (CI 0.68-1.07, p =NS). Multivariate analysis: HR 0.86 (CI 0.67-1.11, 
p=NS).
conclusion: While prior studies have shown increased mortality in women with VADs, this study demonstrates that women surviving to HT have 
similar survival post-HT. While there was a trend towards increased LVAD utilization in women, this was not statistically significant. These findings are 
surprising in light of the Heartmate II availability, permitting use in those with lower BMI.
 
